2,363 Shares in Abbott Laboratories (NYSE:ABT) Purchased by Chemistry Wealth Management LLC

Chemistry Wealth Management LLC purchased a new position in shares of Abbott Laboratories (NYSE:ABT - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 2,363 shares of the healthcare product maker's stock, valued at approximately $267,000.

A number of other large investors have also made changes to their positions in the company. Relyea Zuckerberg Hanson LLC raised its holdings in Abbott Laboratories by 173.0% during the 4th quarter. Relyea Zuckerberg Hanson LLC now owns 23,609 shares of the healthcare product maker's stock worth $2,670,000 after buying an additional 14,960 shares during the period. Avanza Fonder AB acquired a new stake in shares of Abbott Laboratories during the fourth quarter worth $20,636,000. Everpar Advisors LLC lifted its position in Abbott Laboratories by 4.7% in the 4th quarter. Everpar Advisors LLC now owns 2,957 shares of the healthcare product maker's stock valued at $334,000 after acquiring an additional 134 shares in the last quarter. Tompkins Financial Corp boosted its stake in Abbott Laboratories by 2.4% in the 4th quarter. Tompkins Financial Corp now owns 104,215 shares of the healthcare product maker's stock worth $11,788,000 after purchasing an additional 2,410 shares during the period. Finally, Woodstock Corp increased its holdings in Abbott Laboratories by 0.7% during the 4th quarter. Woodstock Corp now owns 132,469 shares of the healthcare product maker's stock worth $14,984,000 after purchasing an additional 940 shares in the last quarter. Institutional investors own 75.18% of the company's stock.

Abbott Laboratories Stock Performance

Shares of ABT traded down $0.46 during trading hours on Friday, hitting $113.45. The company had a trading volume of 6,443,213 shares, compared to its average volume of 4,199,178. The firm has a market cap of $196.78 billion, a price-to-earnings ratio of 34.48, a PEG ratio of 2.40 and a beta of 0.73. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32. The business has a fifty day moving average of $114.93 and a 200-day moving average of $112.73. Abbott Laboratories has a 12 month low of $99.71 and a 12 month high of $121.64.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Wednesday, October 16th. The healthcare product maker reported $1.21 EPS for the quarter, beating the consensus estimate of $1.20 by $0.01. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.99%. The company had revenue of $10.64 billion for the quarter, compared to the consensus estimate of $10.55 billion. During the same quarter in the prior year, the business earned $1.14 earnings per share. The firm's revenue for the quarter was up 4.9% on a year-over-year basis. Equities analysts anticipate that Abbott Laboratories will post 4.67 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Wednesday, January 15th will be given a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a yield of 2.08%. This is a positive change from Abbott Laboratories's previous quarterly dividend of $0.55. The ex-dividend date is Wednesday, January 15th. Abbott Laboratories's dividend payout ratio (DPR) is currently 66.87%.

Wall Street Analyst Weigh In

ABT has been the topic of a number of research reports. Barclays boosted their price target on Abbott Laboratories from $143.00 to $149.00 and gave the company an "overweight" rating in a report on Tuesday, November 5th. Evercore ISI upped their price target on Abbott Laboratories to $136.00 and gave the stock a "buy" rating in a research report on Thursday, January 2nd. Royal Bank of Canada lifted their price objective on shares of Abbott Laboratories from $125.00 to $130.00 and gave the company an "outperform" rating in a report on Tuesday, October 8th. Jefferies Financial Group raised their target price on shares of Abbott Laboratories from $120.00 to $125.00 and gave the company a "hold" rating in a research report on Thursday, October 17th. Finally, Sanford C. Bernstein boosted their price target on shares of Abbott Laboratories from $133.00 to $138.00 and gave the stock an "outperform" rating in a research report on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. According to data from MarketBeat, Abbott Laboratories has an average rating of "Moderate Buy" and a consensus price target of $131.57.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.